Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (NASDAQ: APRE) is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The company’s pioneering research aims to develop and commercialize cancer therapeutics that target the DNA damage response (DDR) pathways. Aprea's lead product candidate, ATRN-119, is a macrocyclic ATR inhibitor designed for treating solid tumors with DDR-related gene mutations. This inhibitor is currently in a Phase 1/2a clinical trial and has shown promising preliminary data, being well tolerated with no dose-limiting toxicities.
Another key candidate, APR-1051, is a highly selective WEE1 kinase inhibitor. The company recently received FDA clearance for an Investigational New Drug (IND) application for APR-1051, enabling the initiation of a Phase 1 clinical trial aimed at treating cancers that overexpress Cyclin E, including ovarian and breast cancers. Preclinical studies have demonstrated APR-1051's potential low toxicity and high selectivity, making it a candidate for best-in-class treatment.
Aprea’s commitment to advancing precision oncology is underscored by recent financial results and corporate developments. For instance, as of March 31, 2024, the company reported $32.4 million in cash and cash equivalents. Notably, Aprea has secured a private placement financing of up to $34 million to support its ongoing and upcoming clinical trials. Furthermore, Aprea’s strong leadership team, including newly appointed Chief Medical Officer Dr. Nadeem Q. Mirza, continues to drive the company’s strategic initiatives.
Recent achievements include the presentation of promising preclinical and clinical data at major conferences such as the AACR Annual Meeting. These presentations highlighted the potential of ATRN-119 and APR-1051 in treating cancers with specific genetic mutations, reinforcing Aprea’s potential to fill significant unmet medical needs in oncology.
For more detailed information about Aprea Therapeutics and its innovative approaches to cancer treatment, please visit their website at www.aprea.com.
Aprea Therapeutics (Nasdaq: APRE) reported financial results for 2022, highlighting its focus on developing cancer therapeutics targeting DNA damage response pathways. The company initiated its Phase 1/2a clinical trial for ATR inhibitor ATRN-119 and secured approximately $5.5 million from a public offering to extend its cash runway to Q3 2024. Cash and equivalents stood at $28.8 million as of December 31, 2022. Aprea experienced a reduced operating loss of $2.7 million in Q4 2022, down from $7.8 million in Q4 2021. The year-end net loss was $112.7 million, a significant increase from $37.1 million in 2021, primarily due to acquired in-process research and development costs.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the selection of its abstract on preclinical programs ATRN-119 and ATRN-W1051 for presentation at the AACR 2023 Annual Meeting in Orlando, Florida, scheduled for April 14-19, 2023. The poster, titled 'ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment,' will be presented on April 19 at 9:00 am ET, focusing on DNA damage response pathways in cancer treatment. Aprea is committed to developing synthetic lethality cancer therapeutics, with ATRN-119 currently in clinical stages for solid tumors and plans for WEE1 inhibitor IND submission.
Aprea Therapeutics, a biopharmaceutical company focused on cancer therapeutics, announced that CEO Oren Gilad will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 a.m. ET. The presentation will provide a corporate overview and will be accessible via a live webcast on the company's website, followed by a replay available for 90 days. Aprea is developing innovative drugs targeting DNA damage response pathways, with its lead program being ATRN-119, aimed at treating solid tumors. The company emphasizes its commitment to disclosing material information via its investor relations platform.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Select Market. This achievement follows a recent financing round supported by quality institutions, which strengthened its balance sheet. Aprea is focused on developing cancer therapeutics targeting DNA damage response pathways, with its lead program being ATRN-119, currently in clinical trials. The company is also advancing a WEE1 inhibitor toward IND submission.
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the closing of a public offering of 1,050,000 shares at $5.25 per share, generating gross proceeds of approximately $5.5 million. The offering includes a 30-day option for underwriters to purchase an additional 157,500 shares. Net proceeds will fund the development of clinical asset ATRN-119 and pre-clinical asset ATRN-W1051, along with general corporate purposes. The offering was conducted under an effective shelf registration statement filed with the SEC. Maxim Group LLC served as the sole book-running manager.
FAQ
What is the current stock price of Aprea Therapeutics (APRE)?
What is the market cap of Aprea Therapeutics (APRE)?
What is Aprea Therapeutics' main focus?
What are Aprea Therapeutics' lead product candidates?
What is the current status of ATRN-119?
What recent achievement is related to APR-1051?
How is Aprea Therapeutics funded for its clinical trials?
Who is the newly appointed Chief Medical Officer at Aprea Therapeutics?
What significant events did Aprea participate in recently?
What are some unique attributes of ATRN-119?
What is Aprea's approach to addressing unmet medical needs in oncology?
Where can I find more information about Aprea Therapeutics?
